Medical University of Vienna

Disease modeling and organoid technology (DMOT) research group

Skin & Endothelial research division (SERD)
Department of Dermatology
Lazarettgasse 14a, 1090 Vienna, Austria
Tel: +43-(0)1 40 4000 58320

e-mail: benedikt.weber@meduniwien.ac.at

homepage:

https://www.meduniwien.ac.at/hp/dermatologie/wissenschaft-forschung/weber-lab-disease-modeling-and-organoid-technology-dmot-research-group/

know-how and research interests:

The “disease modeling and organoid technology” (DMOT) research group at the Department of Dermatology at the Medical University of Vienna focuses on the development of in vitro and in vivo models of human diseases with a particular focus on vascular diseases affecting the skin. Our lab combines clinical research with cutting-edge laboratory techniques with the ultimate goal of developing novel pharmaceutical approaches. This involves cellular reprogramming techniques, induced pluripotent stem cells, multipotent (adult) stem cells, in vitro (and in situ) tissue engineering approaches, pulsatile flow bioreactor systems, computational modeling as well as small animal in vivo models. The research group is embedded in the infrastructure of the “Skin and Endothelium Research Division” at the Anna-Spiegel Research building of the Medical University of Vienna, Austria.

research topic (general title):

Vascular disease modeling

techniques and infrastructure of the research group:

Infrastructure of the Skin & Endothelial research division (www.serd.at) and the Department of Dermatology (https://www.meduniwien.ac.at/hp/dermatologie/)

5 selected publications:

Generali M, Casanova EA, Kehl D, Wanner D, Hoerstrup SP, Cinelli P*, Weber B*. Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells. Acta Biomater. 2019 Oct 1;97:333-343.

Mallone A, Stenger C, Von Eckardstein A, Hoerstrup SP, Weber B. Biofabricating atherosclerotic plaques: In vitro engineering of a three-dimensional human fibroatheroma model. Biomaterials. 2018 Jan;150:49-59.

Slamecka J, Salimova L, McClellan S, van Kelle M, Kehl D, Laurini J, Gross N, Cinelli P, Achermann J, Owen L*, Hoerstrup SP*, Weber B*. Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluri potent stem cells in chemically defined xeno-freeconditions. Cell Cycle. 2015 Dec 10:0.

Weber B, Emmert MY, Behr L, Schoenauer R, Drogemueler C, Roschitzki B, Modregger P, Stampanoni M, Vats D, Buerzle W, Farine M, Mazza E, Brokopp C, Frauenfelder T, Zannettino AE, Zünd G, Kretschmar O, Falk V, Hoerstrup SP. Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials 2012; 33(16):4031-43.

Weber B*, Scherman J*, Emmert MY*, Gruenenfelder J, Verbeek R, Bracher M, Black M, Kortsmit J, Franz T, Schoenauer R, Baumgartner L, Brokopp C, Agarkova I, Wolint P, Zund G, Falk V, Zilla P, Hoerstrup SP. Injectable living marrow stromal cell-based autologous tissue engineered heart valves. European Heart Journal 2011; 32(22):2830-40."